These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10340171)

  • 1. Vaccines and antibodies in the prevention and treatment of sepsis.
    Bhattacharjee AK; Cross AS
    Infect Dis Clin North Am; 1999 Jun; 13(2):355-69, vii. PubMed ID: 10340171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunization with a detoxified endotoxin vaccine protects against lethal polymicrobial sepsis: its use with CpG adjuvant and potential mechanisms.
    Opal SM; Palardy JE; Chen WH; Parejo NA; Bhattacharjee AK; Cross AS
    J Infect Dis; 2005 Dec; 192(12):2074-80. PubMed ID: 16288370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protection by anti-core glycolipid antibodies: evidence from animal experiments.
    Hustinx WN; Kraaijeveld K; Hoepelman AI; Verhoef J
    J Antimicrob Chemother; 1997 Oct; 40(4):475-83. PubMed ID: 9372415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprophylaxis and immunotherapy of gram-negative sepsis and shock with antibodies to core glycolipids and lipid A of bacterial lipopolysaccharides.
    Mitov IG; Terziiski DG
    Infection; 1991; 19(6):383-90. PubMed ID: 1816107
    [No Abstract]   [Full Text] [Related]  

  • 5. Passive immunotherapy of gram-negative bacteremia, sepsis and septic shock.
    Spapen HD; Diltoer M; Huyghens LP
    Acta Clin Belg; 1993; 48(1):20-9. PubMed ID: 7684546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in our understanding of sepsis: evaluation of anti-endotoxin antibodies and biological response modifiers.
    Talan DA
    Ann Emerg Med; 1993 Dec; 22(12):1871-90. PubMed ID: 8239111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilot study of anti-lipopolysaccharide human monoclonal antibody MAB-T88 in patients with gram-negative sepsis.
    Daifuku R; Panacek EA; Haenftling K; Swenson WK; Prescott AW; Johnson JL
    Hum Antibodies Hybridomas; 1993 Jan; 4(1):36-9. PubMed ID: 8431557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of gram-negative bacteremia with antiserum to core glycolipid. I. The experimental basis of immunity to endotoxin.
    Ziegler EJ; McCutchan JA; Braude AI
    Eur J Cancer (1965); 1979; 15 Suppl():71-6. PubMed ID: 397063
    [No Abstract]   [Full Text] [Related]  

  • 10. Endotoxin-based molecular strategies for the prevention and treatment of gram-negative sepsis and septic shock.
    Pollack M; Ohl CA
    Curr Top Microbiol Immunol; 1996; 216():275-97. PubMed ID: 8791745
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-endotoxin vaccines: back to the future.
    Cross AS
    Virulence; 2014 Jan; 5(1):219-25. PubMed ID: 23974910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The dynamics of the antibody titers to Re-glycolipid in peritonitis patients during the performance of antiendotoxin immunotherapy].
    Apollonin AV; Rudik AA; Goldobina TV; Kropacheva EI; Likhoded VG
    Zh Mikrobiol Epidemiol Immunobiol; 1994; (6):88-9. PubMed ID: 7879563
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunotherapy of sepsis: flawed concept or faulty implementation?
    Cross AS; Opal SM; Bhattacharjee AK; Donta ST; Peduzzi PN; Fürer E; Que JU; Cryz SJ
    Vaccine; 1999 Oct; 17 Suppl 2():S13-21. PubMed ID: 10506404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an anti-core lipopolysaccharide vaccine for the prevention and treatment of sepsis.
    Cross AS; Opal S; Cook P; Drabick J; Bhattacharjee A
    Vaccine; 2004 Feb; 22(7):812-7. PubMed ID: 15040932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies to endotoxin in the management of sepsis.
    Fang KC
    West J Med; 1993 Apr; 158(4):393-9. PubMed ID: 8317126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of gram-negative sepsis in man with anti-endotoxin antibodies: a review.
    Wortel CH; Ziegler EJ; van Deventer SJ
    Prog Clin Biol Res; 1991; 367():161-78. PubMed ID: 1924425
    [No Abstract]   [Full Text] [Related]  

  • 19. Antiendotoxin monoclonal antibodies for gram-negative sepsis.
    Chmel H; Emmanuel G
    Clin Infect Dis; 1992 Aug; 15(2):371-2. PubMed ID: 1520771
    [No Abstract]   [Full Text] [Related]  

  • 20. Antibody to endotoxin in the treatment of gram-negative sepsis.
    Schentag JJ
    JAMA; 1992 May; 267(17):2326-7. PubMed ID: 1564766
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.